Cargando…

Corrigendum: Efficacy and safety of riociguat replacing PDE-5is for patients with pulmonary arterial hypertension: A systematic review and meta-analysis

Detalles Bibliográficos
Autores principales:	Liu, Yu-Yang, Qu, Yi-Yang, Wang, Shang, Luo, Ci-Jun, Qiu, Hong-Ling, Li, Hui-Ting, Yuan, Ping, Wang, Lan, Li, Jin-Ling, Jiang, Rong, Zhang, Rui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9987690/ https://www.ncbi.nlm.nih.gov/pubmed/36891269 http://dx.doi.org/10.3389/fphar.2023.1155631

Ejemplares similares

Efficacy and safety of riociguat replacing PDE-5is for patients with pulmonary arterial hypertension: A systematic review and meta-analysis
por: Liu, Yu-Yang, et al.
Publicado: (2023)

Corrigendum: Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model
por: Morales-Cano, Daniel, et al.
Publicado: (2023)

Case report: a patient with pulmonary arterial hypertension transitioning from a PDE-5 inhibitor to Riociguat
por: Poch, David S.
Publicado: (2016)

Balloon pulmonary angioplasty combined with riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (PRACTICE study): study protocol for a randomized controlled trial
por: Zhao, Qin-Hua, et al.
Publicado: (2021)

Efficacy and safety of riociguat in the treatment of chronic thromboembolic pulmonary arterial hypertension: A meta-analysis
por: Ying, Miaofa, et al.
Publicado: (2021)

Effects of riociguat in severe experimental pulmonary hypertension
por: Kojonazarov, Baktybek, et al.
Publicado: (2011)

Riociguat: Something new in pulmonary hypertension therapeutics?
por: Shanmugam, Elangovan, et al.
Publicado: (2015)

Baicalein Ameliorates Aβ-Induced Memory Deficits and Neuronal Atrophy via Inhibition of PDE2 and PDE4
por: Shi, Jing, et al.
Publicado: (2021)

Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model
por: Morales-Cano, Daniel, et al.
Publicado: (2023)

Perspectives of PDE inhibitor on treating idiopathic pulmonary fibrosis
por: Yang, Xudan, et al.
Publicado: (2023)

Practical management of riociguat in patients with pulmonary arterial hypertension
por: Halank, Michael, et al.
Publicado: (2019)

Overview of Riociguat and Its Role in the Treatment of Pulmonary Hypertension
por: Kenny, Marianne, et al.
Publicado: (2020)

Efficacy and safety of riociguat in combination therapy for patients with pulmonary arterial hypertension (PATENT studies)
por: Ghofrani, Hossein-Ardeschir, et al.
Publicado: (2020)

Differential Expression and Function of PDE8 and PDE4 in Effector T cells: Implications for PDE8 as a Drug Target in Inflammation
por: Vang, Amanda G., et al.
Publicado: (2016)

Riociguat for the treatment of pulmonary hypertension: Chinese subgroup analyses and comparison
por: Wang, Chen, et al.
Publicado: (2016)

Riociguat and the right ventricle in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
por: Benza, Raymond L., et al.
Publicado: (2022)

Riociguat for pulmonary arterial hypertension associated with congenital heart disease
por: Rosenkranz, Stephan, et al.
Publicado: (2015)

Riociguat in children with pulmonary arterial hypertension: The PATENT–CHILD study
por: García Aguilar, Humberto, et al.
Publicado: (2022)

Corrigendum: BI 1015550 is a PDE4B inhibitor and a clinical drug candidate for the oral treatment of idiopathic pulmonary fibrosis
por: Herrmann, Franziska Elena, et al.
Publicado: (2023)

Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertension
por: Kim, Nick H, et al.
Publicado: (2017)

The regulatory role of PDE4B in the progression of inflammatory function study
por: Su, Yue, et al.
Publicado: (2022)

Treatment of patients with chronic thrombo embolic pulmonary hypertension: focus on riociguat
por: Smith, Zachary R, et al.
Publicado: (2016)

Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension
por: Lian, Tian-Yu, et al.
Publicado: (2017)

PDE4 and PDE5 regulate cyclic nucleotide contents and relaxing effects on carbachol-induced contraction in the bovine abomasum
por: KANEDA, Takeharu, et al.
Publicado: (2014)

Corrigendum: Identification of Hypoxia Induced Metabolism Associated Genes in Pulmonary Hypertension
por: He, Yang-Yang, et al.
Publicado: (2021)

The Efficacy and Safety of Pulmonary Vasodilators in Pediatric Pulmonary Hypertension (PH): A Systematic Review and Meta-analysis
por: Shu, Tingting, et al.
Publicado: (2021)

Long-term clinical value and outcome of riociguat in chronic thromboembolic pulmonary hypertension
por: van Thor, M.C.J., et al.
Publicado: (2019)

Triple oral combination therapy with macitentan, riociguat, and selexipag for pulmonary arterial hypertension
por: Momoi, Mizuki, et al.
Publicado: (2021)

Evaluating Riociguat in the Treatment of Pulmonary Arterial Hypertension: A Real-World Perspective
por: Mihalek, Andrew D, et al.
Publicado: (2022)

Riociguat dose titration in patients with chronic thromboembolic pulmonary hypertension (CTEPH) or pulmonary arterial hypertension (PAH)
por: Ghofrani, Hossein A, et al.
Publicado: (2009)

Initial Riociguat Monotherapy and Transition from Sildenafil to Riociguat in Patients with Idiopathic Pulmonary Arterial Hypertension: Influence on Right Heart Remodeling and Right Ventricular–Pulmonary Arterial Coupling
por: Taran, Irina N., et al.
Publicado: (2018)

Replacing a phosphodiesterase-5 inhibitor with riociguat in patients with connective tissue disease-associated pulmonary arterial hypertension: a case series
por: Raina, Amresh, et al.
Publicado: (2017)

Corrigendum: Pharmacokinetics, Immunogenicity and Safety Study for SHR-1309 Injection and Perjeta(®) in Healthy Chinese Male Volunteers
por: Cui, Yingzi, et al.
Publicado: (2022)

Corrigendum: Metabonomic analysis of the anti-hepatic fibrosis effect of Ganlong capsules
por: Lv, ChangLing, et al.
Publicado: (2023)

Assessment of the REPLACE study composite endpoint in riociguat-treated patients in the PATENT study
por: Simonneau, Gérald, et al.
Publicado: (2020)

PDE5 Inhibitors as Potential Tools in the Treatment of Cystic Fibrosis
por: Noel, Sabrina, et al.
Publicado: (2012)

Riociguat prevents hyperoxia-induced lung injury and pulmonary hypertension in neonatal rats without effects on long bone growth
por: Donda, Keyur, et al.
Publicado: (2018)

Rolipram, a PDE4 Inhibitor, Enhances the Inotropic Effect of Rat Heart by Activating SERCA2a
por: Huang, Huili, et al.
Publicado: (2019)

Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study
por: McLaughlin, Vallerie V., et al.
Publicado: (2017)

Clinical and hemodynamic benefit of macitentan and riociguat upfront combination in patients with pulmonary arterial hypertension
por: Sulica, Roxana, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_vegfvr3cmjqmddpq3p0p64cple